Commonly, heterozygous inactivating pathogenic variants of the CASR gene lead to FHH, whilst homozygous or compound heterozygous inactivating mutations cause severe neonatal hyperparathyroidism [2]. This evidence concerns the gene CASR and neonatal severe primary hyperparathyroidism.